CO2021007973A2 - Compuestos de 3-((3-aminofenil)amino)piperidina-2,6-diona sustituida, composiciones de estos y métodos de tratamiento con estos - Google Patents

Compuestos de 3-((3-aminofenil)amino)piperidina-2,6-diona sustituida, composiciones de estos y métodos de tratamiento con estos

Info

Publication number
CO2021007973A2
CO2021007973A2 CONC2021/0007973A CO2021007973A CO2021007973A2 CO 2021007973 A2 CO2021007973 A2 CO 2021007973A2 CO 2021007973 A CO2021007973 A CO 2021007973A CO 2021007973 A2 CO2021007973 A2 CO 2021007973A2
Authority
CO
Colombia
Prior art keywords
compositions
methods
aminophenyl
piperidine
amino
Prior art date
Application number
CONC2021/0007973A
Other languages
English (en)
Spanish (es)
Inventor
Matthew D Correa
Joshua Hansen
Mark A Nagy
Massimo Ammirante
Sogoie Bahmanyar
Virginia Grant
Evan J Horn
Timothy S Kercher
Christopher Mayne
Rama Krishna Narla
Surendra Nayak
Stephen Norris
Patrick Papa
Veronique Plantevin-Krenitsky
John J Sapienza
Brandon W Whitefield
Shuichan Su
Original Assignee
Celgene Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Celgene Corp filed Critical Celgene Corp
Publication of CO2021007973A2 publication Critical patent/CO2021007973A2/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/92—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with a hetero atom directly attached to the ring nitrogen atom
    • C07D211/94—Oxygen atom, e.g. piperidine N-oxide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/04—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
    • C07D233/28—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D233/30—Oxygen or sulfur atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/08—Bridged systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
CONC2021/0007973A 2018-12-19 2021-06-18 Compuestos de 3-((3-aminofenil)amino)piperidina-2,6-diona sustituida, composiciones de estos y métodos de tratamiento con estos CO2021007973A2 (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862782298P 2018-12-19 2018-12-19
US201962879900P 2019-07-29 2019-07-29
PCT/US2019/067088 WO2020132014A1 (en) 2018-12-19 2019-12-18 Substituted 3-((3-aminophenyl)amino)piperidine-2,6-dione compounds, compositions thereof, and methods of treatment therewith

Publications (1)

Publication Number Publication Date
CO2021007973A2 true CO2021007973A2 (es) 2021-09-09

Family

ID=71098067

Family Applications (1)

Application Number Title Priority Date Filing Date
CONC2021/0007973A CO2021007973A2 (es) 2018-12-19 2021-06-18 Compuestos de 3-((3-aminofenil)amino)piperidina-2,6-diona sustituida, composiciones de estos y métodos de tratamiento con estos

Country Status (29)

Country Link
US (4) US11149007B2 (cg-RX-API-DMAC7.html)
EP (2) EP3897636B1 (cg-RX-API-DMAC7.html)
JP (2) JP7494181B2 (cg-RX-API-DMAC7.html)
KR (2) KR20250144505A (cg-RX-API-DMAC7.html)
CN (2) CN113453681B (cg-RX-API-DMAC7.html)
AU (1) AU2019403207B2 (cg-RX-API-DMAC7.html)
BR (1) BR112021011968A2 (cg-RX-API-DMAC7.html)
CA (1) CA3124130A1 (cg-RX-API-DMAC7.html)
CL (1) CL2021001665A1 (cg-RX-API-DMAC7.html)
CO (1) CO2021007973A2 (cg-RX-API-DMAC7.html)
DK (1) DK3897636T3 (cg-RX-API-DMAC7.html)
ES (1) ES3009308T3 (cg-RX-API-DMAC7.html)
FI (1) FI3897636T3 (cg-RX-API-DMAC7.html)
HR (1) HRP20250095T1 (cg-RX-API-DMAC7.html)
HU (1) HUE070506T2 (cg-RX-API-DMAC7.html)
IL (1) IL284223B2 (cg-RX-API-DMAC7.html)
LT (1) LT3897636T (cg-RX-API-DMAC7.html)
MX (1) MX2021007473A (cg-RX-API-DMAC7.html)
MY (1) MY205718A (cg-RX-API-DMAC7.html)
PE (1) PE20212247A1 (cg-RX-API-DMAC7.html)
PL (1) PL3897636T3 (cg-RX-API-DMAC7.html)
PT (1) PT3897636T (cg-RX-API-DMAC7.html)
RS (1) RS66556B1 (cg-RX-API-DMAC7.html)
SG (1) SG11202106507RA (cg-RX-API-DMAC7.html)
SI (1) SI3897636T1 (cg-RX-API-DMAC7.html)
SM (1) SMT202500111T1 (cg-RX-API-DMAC7.html)
TW (1) TWI820276B (cg-RX-API-DMAC7.html)
WO (1) WO2020132014A1 (cg-RX-API-DMAC7.html)
ZA (1) ZA202104200B (cg-RX-API-DMAC7.html)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR112021011968A2 (pt) * 2018-12-19 2021-09-08 Celgene Corporation Compostos de 3-((3-aminofenil)amino)piperidina-2,6-diona substituídos, composições dos mesmos e métodos de tratamento com os mesmos
AU2019404022A1 (en) 2018-12-19 2021-07-08 Celgene Corporation Substituted 3-((3-aminophenyl)amino)piperidine-2,6-dione compounds, compositions thereof, and methods of treatment therewith
WO2021127443A1 (en) 2019-12-19 2021-06-24 Arvinas Operations, Inc. Compounds and methods for the targeted degradation of androgen receptor
CN115996918A (zh) 2020-05-09 2023-04-21 阿尔维纳斯运营股份有限公司 制造双官能团化合物的方法、双官能团化合物的超纯形式以及包括所述双官能团化合物的剂型
ES3047718T3 (en) 2020-06-24 2025-12-04 Celgene Corp Cereblon binding compounds, compositions thereof, and methods of treatment therewith
JP7778095B2 (ja) 2020-06-24 2025-12-01 セルジーン コーポレーション セレブロン結合化合物、その組成物及びそれによる治療方法
IL299256A (en) 2020-06-24 2023-02-01 Celgene Corp Cerebellum binding compounds, their compounds and methods of treatment with them
WO2022019597A1 (ko) * 2020-07-21 2022-01-27 주식회사 유빅스테라퓨틱스 안드로겐 수용체 분해용 화합물 및 이들의 의약 용도
US20240025863A1 (en) 2020-09-16 2024-01-25 Biotheryx, Inc. Sos1 protein degraders, pharmaceutical compositions thereof, and their therapeutic applications
TW202231269A (zh) 2020-10-23 2022-08-16 美商拜歐斯瑞克斯公司 Kras蛋白降解劑、其醫藥組合物及其治療應用
US20240124418A1 (en) 2020-12-14 2024-04-18 Biotheryx, Inc. Pde4 degraders, pharmaceutical compositions, and therapeutic applications
AU2022240688B2 (en) * 2021-03-17 2024-07-11 Shanghai Qilu Pharmaceutical Research And Development Centre Ltd. Furan fused ring-substituted glutarimide compound
EP4359404A4 (en) * 2021-06-25 2025-06-04 Celgene Corporation Cereblon-binding compounds, compositions thereof and methods of treatment therewith
KR20240026939A (ko) * 2021-06-25 2024-02-29 셀진 코포레이션 세레블론 결합 화합물, 이의 조성물, 및 이에 의한 치료 방법
KR20240026946A (ko) * 2021-06-25 2024-02-29 셀진 코포레이션 세레블론 결합 화합물, 이의 조성물, 및 이에 의한 치료 방법
US12419962B2 (en) 2022-03-16 2025-09-23 Biotheryx, Inc. Quinazolines, pharmaceutical compositions, and therapeutic applications
US20260174749A1 (en) * 2022-11-09 2026-06-25 Bristol-Myers Squibb Company Combination therapy with substituted 3-((3-aminophenyl)amino)piperidine-2,6- dione compounds
AU2024392985A1 (en) 2023-12-08 2026-06-04 Arvinas Operations, Inc. Use of androgen receptor degrader for the treatment of spinal and bulbar muscular atrophy
WO2025235600A1 (en) * 2024-05-07 2025-11-13 Bristol-Myers Squibb Company Processes for the preparation of substituted 3-((3-aminophenyl)amino) piperidine-2,6-dione compounds
WO2025235577A1 (en) * 2024-05-09 2025-11-13 Bristol-Myers Squibb Company Forms and formulations of substituted 3-((3-amino)piperidine-2,6-dione compounds
CN118993935B (zh) * 2024-10-23 2025-02-14 江苏恒瑞医药股份有限公司 咪唑啉衍生物或其盐的制备方法

Family Cites Families (44)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE4302485A1 (de) 1993-01-29 1994-08-04 Merck Patent Gmbh Piperazinderivate
HU228769B1 (en) 1996-07-24 2013-05-28 Celgene Corp Substituted 2(2,6-dioxopiperidin-3-yl)phthalimides and -1-oxoisoindolines and their use for production of pharmaceutical compositions for mammals to reduce the level of tnf-alpha
FR2768729A1 (fr) 1997-09-19 1999-03-26 Rhodia Chimie Sa Procede d'acylation d'un compose aromatique et complexes catalytiques
FR2768728B1 (fr) 1997-09-19 1999-12-03 Rhodia Chimie Sa Procede d'acylation d'un compose aromatique
US7629360B2 (en) 1999-05-07 2009-12-08 Celgene Corporation Methods for the treatment of cachexia and graft v. host disease
KR20070106969A (ko) 2004-09-09 2007-11-06 추가이 세이야쿠 가부시키가이샤 신규 이미다졸리딘 유도체 및 그 용도
WO2007073432A2 (en) 2005-10-11 2007-06-28 Chemocentryx, Inc. Piperidine derivatives and methods of use
WO2007136640A2 (en) 2006-05-16 2007-11-29 Celgene Corporation Processes for the preparation of substituted 2-(2,6-dioxopiperidin-3-yl)isoindole-1,3-dione
WO2011008260A2 (en) 2009-07-13 2011-01-20 President And Fellows Of Harvard College Bifunctional stapled polypeptides and uses thereof
RU2434851C1 (ru) * 2010-07-22 2011-11-27 Александр Васильевич Иващенко Циклические n, n'-диарилтиомочевины или n, n'-диарилмочевины - антагонисты андрогенных рецепторов, противораковое средство, способ получения и применения
US8765978B2 (en) 2010-12-16 2014-07-01 Transitions Optical, Inc. Method of making indeno-fused naphthol materials
WO2012119559A1 (en) 2011-03-10 2012-09-13 Suzhou Kintor Pharmaceuticals,Inc. Androgen receptor antagonists and uses thereof
US20140112922A1 (en) 2011-03-28 2014-04-24 Cornell University Targeted protein silencing using chimeras between antibodies and ubiquitination enzymes
KR102438072B1 (ko) 2012-01-12 2022-08-31 예일 유니버시티 E3 유비퀴틴 리가아제에 의한 표적 단백질 및 다른 폴리펩티드의 증진된 분해를 위한 화합물 및 방법
SI2894151T1 (sl) * 2012-09-04 2021-01-29 Shanghai Hengrui Pharmaceutical Co. Ltd. Imidazolinski derivati, postopki za njihovo pripravo in njihove uporabe v medicini
USRE48175E1 (en) 2012-10-19 2020-08-25 Dana-Farber Cancer Institute, Inc. Hydrophobically tagged small molecules as inducers of protein degradation
KR102226587B1 (ko) 2013-01-31 2021-03-11 버텍스 파마슈티칼스 인코포레이티드 나트륨 채널의 조절제로서의 퀴놀린 및 퀴나졸린 아미드
US20160058872A1 (en) 2014-04-14 2016-03-03 Arvinas, Inc. Imide-based modulators of proteolysis and associated methods of use
EP4649963A3 (en) 2014-04-14 2026-05-13 Arvinas Operations, Inc. Imide-based modulators of proteolysis and associated methods of use
RU2557235C1 (ru) 2014-07-08 2015-07-20 Александр Васильевич Иващенко Замещенные 2-тиоксо-имидазолидин-4-оны и их спироаналоги, противораковый активный компонент, фармацевтическая композиция, лекарственный препарат, способ лечения рака простаты
US9694084B2 (en) 2014-12-23 2017-07-04 Dana-Farber Cancer Institute, Inc. Methods to induce targeted protein degradation through bifunctional molecules
JP6815318B2 (ja) 2014-12-23 2021-01-20 ダナ−ファーバー キャンサー インスティテュート,インコーポレイテッド 二官能性分子によって標的化タンパク質分解を誘導する方法
JP6817962B2 (ja) 2015-01-20 2021-01-20 アルビナス・オペレーションズ・インコーポレイテッドArvinas Operations, Inc. ターゲティングされたアンドロゲン受容体分解のための化合物および方法
AU2016232705C1 (en) 2015-03-18 2021-06-17 Arvinas, Inc. Compounds and methods for the enhanced degradation of targeted proteins
GB201506871D0 (en) 2015-04-22 2015-06-03 Glaxosmithkline Ip Dev Ltd Novel compounds
EP3319944A4 (en) 2015-07-10 2019-04-24 Arvinas, Inc. MDM2-BASED MODULATORS OF PROTEOLYSIS AND RELATED USE METHODS
EP3337476A4 (en) 2015-08-19 2019-09-04 Arvinas, Inc. Compounds and methods for the targeted degradation of bromodomain-containing proteins
TWI726969B (zh) 2016-01-11 2021-05-11 比利時商健生藥品公司 用作雄性激素受體拮抗劑之經取代之硫尿囊素衍生物
WO2017197046A1 (en) 2016-05-10 2017-11-16 C4 Therapeutics, Inc. C3-carbon linked glutarimide degronimers for target protein degradation
WO2018009694A1 (en) 2016-07-08 2018-01-11 Janssen Pharmaceutica Nv Thiohydantoin androgen receptor antagonists for the treatment of cancer
TWI739888B (zh) 2016-10-07 2021-09-21 美商陶氏農業科學公司 農藥組合物及方法
SI3526202T1 (sl) 2016-10-11 2025-04-30 Arvinas Operations, Inc. Spojine in postopki za ciljno razgradnjo androgenskih receptorjev
WO2018089736A1 (en) 2016-11-10 2018-05-17 Dana-Farber Cancer Institute, Inc. Degradation of protein kinases by conjugation of protein kinase inhibitors with e3 ligase ligand and methods of use
AU2017363257B2 (en) 2016-11-22 2021-08-19 Dana-Farber Cancer Institute, Inc. Degradation of protein kinases by conjugation of protein kinase inhibitors with E3 ligase ligand and methods of use
RU2747260C2 (ru) 2016-12-19 2021-04-29 Аббиско Тхерапеутицс Цо., Лтд. Ингибитор рфрф4, способ его получения и его фармацевтическое применение
IL319363A (en) 2017-01-31 2025-05-01 Arvinas Operations Inc Cervalon ligands and bifunctional compounds containing them
EP4717317A3 (en) 2017-06-20 2026-06-03 C4 Therapeutics, Inc. N/o-linked degrons and degronimers for protein degradation
CN109422725A (zh) 2017-09-04 2019-03-05 北京美倍他药物研究有限公司 前列腺癌治疗药物
HUE064356T2 (hu) 2017-11-28 2024-03-28 Aarti Pharmalabs Ltd Eljárás enzalutamid elõállítására új intermedier felhasználásával
CN111163638B (zh) 2017-12-05 2023-07-25 美国陶氏益农公司 杀有害生物组合物和方法
AU2019276514B2 (en) 2018-05-30 2023-12-14 Jiangsu Hansoh Pharmaceutical Group Co., Ltd. Inhibitor containing tricyclic derivative, preparation method therefor, and application thereof
CN109651256A (zh) 2018-11-20 2019-04-19 上海健康医学院 一种式(viii)的恩杂鲁胺的制备方法
BR112021011968A2 (pt) * 2018-12-19 2021-09-08 Celgene Corporation Compostos de 3-((3-aminofenil)amino)piperidina-2,6-diona substituídos, composições dos mesmos e métodos de tratamento com os mesmos
AU2019404022A1 (en) 2018-12-19 2021-07-08 Celgene Corporation Substituted 3-((3-aminophenyl)amino)piperidine-2,6-dione compounds, compositions thereof, and methods of treatment therewith

Also Published As

Publication number Publication date
KR20250144505A (ko) 2025-10-10
US20240368083A1 (en) 2024-11-07
EP4494711A2 (en) 2025-01-22
IL284223B2 (en) 2025-08-01
MX2021007473A (es) 2021-08-05
US20200199073A1 (en) 2020-06-25
JP7494181B2 (ja) 2024-06-03
IL284223A (en) 2021-08-31
MY205718A (en) 2024-11-07
CL2021001665A1 (es) 2022-01-14
PE20212247A1 (es) 2021-11-24
WO2020132014A1 (en) 2020-06-25
TW202039435A (zh) 2020-11-01
JP2024109765A (ja) 2024-08-14
SG11202106507RA (en) 2021-07-29
US20230002321A1 (en) 2023-01-05
JP2022514344A (ja) 2022-02-10
CN119219606A (zh) 2024-12-31
PT3897636T (pt) 2025-01-27
SI3897636T1 (sl) 2025-04-30
RS66556B1 (sr) 2025-03-31
SMT202500111T1 (it) 2025-05-12
US20260193185A1 (en) 2026-07-09
HRP20250095T1 (hr) 2025-04-11
CA3124130A1 (en) 2020-06-25
EP3897636A4 (en) 2022-09-07
EP4494711A3 (en) 2025-05-21
AU2019403207A1 (en) 2021-07-15
BR112021011968A2 (pt) 2021-09-08
LT3897636T (lt) 2025-03-25
CN113453681B (zh) 2024-10-11
AU2019403207B2 (en) 2025-06-05
US11873283B2 (en) 2024-01-16
CN113453681A (zh) 2021-09-28
DK3897636T3 (da) 2025-01-13
ES3009308T3 (en) 2025-03-26
JP7724911B2 (ja) 2025-08-18
NZ777281A (en) 2025-07-25
PL3897636T3 (pl) 2025-04-28
FI3897636T3 (fi) 2025-02-03
KR20210118816A (ko) 2021-10-01
HUE070506T2 (hu) 2025-06-28
US11149007B2 (en) 2021-10-19
KR102866144B1 (ko) 2025-09-30
EP3897636A1 (en) 2021-10-27
TWI820276B (zh) 2023-11-01
ZA202104200B (en) 2024-11-27
IL284223B1 (en) 2025-04-01
EP3897636B1 (en) 2024-12-11
US12404241B2 (en) 2025-09-02

Similar Documents

Publication Publication Date Title
CL2021001665A1 (es) Compuestos de 3-((3-aminofenil)amino)piperidina-2,6-diona sustituida, composiciones de estos y métodos de tratamiento con estos.
CO2022018653A2 (es) Compuestos de unión a cereblón, composiciones de estos y métodos de tratamiento con estos
MX2021007475A (es) Compuestos de 3-((3-aminofenil)amino)piperidina-2,6-diona sustituida, composiciones de estos y metodos de tratamiento con estos.
CL2021003134A1 (es) Compuestos de 1-oxo-isoindolin-5-carboxamida sustituida, composiciones de estos y métodos de tratamiento con dichos compuestos
CO2020012824A2 (es) Compuestos de 4-aminoisoindolina-1,3-diona sustituidos y su uso para el tratamiento de linfoma
CU24512B1 (es) Derivados de oxopiridina sustituidos
MX389798B (es) Azolopirimidina para el tratamiento de trastornos relacionados con el cáncer.
CO2017003838A2 (es) Compuestos de aminopurina sustituida, composiciones del mismo, y métodos de tratamiento con los mismos
CO2019014484A2 (es) Nuevos derivados de azaquinolina
EP3436018A4 (en) SUBSTITUTED AMINOPURINE COMPOUNDS, COMPOSITIONS AND METHOD FOR TREATING THEREOF
PH12017502106A1 (en) Anthelmintic depsipeptide compounds
PH12018501367A1 (en) Anthelmintic depsipeptide compounds
MX2022001764A (es) Composiciones que comprenden tigolaner para el control de parasitos.
PH12017500569A1 (en) Compositions and methods for the treatment and prophylaxis of surgical site infections
CL2020001107A1 (es) Novedosos derivados de pirazolo-pirrolo-pirimidina como inhibidores de p2x3.
MX2021010252A (es) Inhibidores del receptor de glucocorticoides.
ZA201901168B (en) Novel compounds for treating parasitic disease
CR20170464A (es) Mezcla plaguicida que comprende un compuesto de carboxamida y un bioplaguicida
CO2021004934A2 (es) Composiciones y métodos para tratar retinitis pigmentosa
PA8597501A1 (es) Derivados azabiciclicos de piridiloximetilo y bencisoxazol
CO2021014747A2 (es) Métodos para el tratamiento de βeta-talasemia
MX2022015770A (es) Composicion farmaceutica que comprende un compuesto derivado de benzimidazol.
EA202191713A1 (ru) Замещенные соединения 3-((3-аминофенил)амино)пиперидин-2,6-диона, их композиции и способы лечения с их помощью
BR112019004120A2 (pt) uso de nootkatone para tratar e impedir infestações de mosquito
BR112018073679A2 (pt) composto, composição farmacêutica e método de tratamento de um distúrbio neurodegenerativo